Advertisement
Advertisement
GSK
GSK plc - ADR
56.83
USDSponsored
-0.20
-0.35%
Mar 04, 15:59 UTC -5
Closed
Pre-Market
56.45
-0.38
-0.67%
GSK Earnings Reports
Positive Surprise Ratio
GSK beat 33 of 40 last estimates.
83%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$7.89B
/$0.44
Implied change from Q4 25 (Revenue/ EPS)
-8.49%
/+76.00%
Implied change from Q1 25 (Revenue/ EPS)
+4.93%
/--
GSK plc - ADR earnings per share and revenue
On Feb 04, 2026, GSK reported earnings of 0.25 USD per share (EPS) for Q4 25, beating the estimate of 0.23 USD, resulting in a 8.70% surprise. Revenue reached 8.62 billion, compared to an expected 8.73 billion, with a -1.24% difference. The market reacted with a +7.29% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of 0.44 USD, with revenue projected to reach 7.89 billion USD, implying an increase of 76.00% EPS, and decrease of -8.49% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Liquidia Corporation Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.18
Actual
$0.15
Surprise
-18.48%
Kura Oncology, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.62
Actual
-$0.92
Surprise
-47.84%
CorMedix Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.83
Actual
$0.61
Surprise
-26.73%
Keros Therapeutics, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.64
Actual
-$0.86
Surprise
-34.10%
REGENXBIO Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.97
Actual
-$1.30
Surprise
-33.31%
Lexicon Pharmaceuticals, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.04
Surprise
+43.18%
Verastem, Inc.
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.53
Actual
-$0.50
Surprise
+7.32%
Ocugen, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.06
Surprise
-1.35%
Niagen Bioscience, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
$0.02
Actual
$0.03
Surprise
+33.93%
Aligos Therapeutics, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$1.88
Actual
-$1.91
Surprise
-1.11%
FAQ
What were GSK plc - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, GSK plc - ADR reported EPS of $0.25, beating estimates by 8.7%, and revenue of $8.62B, -1.24% below expectations.
How did the market react to GSK plc - ADR's Q4 2025 earnings?
The stock price moved up 7.29%, changed from $53.34 before the earnings release to $57.23 the day after.
When is GSK plc - ADR expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for GSK plc - ADR's next earnings report?
Based on 5
analysts, GSK plc - ADR is expected to report EPS of $0.44 and revenue of $7.89B for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement